Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2017 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
REVOLUTION MEDICINES INC | 11 | Q2 2024 | 44.0% |
TYRA BIOSCIENCES INC | 11 | Q2 2024 | 16.9% |
ARVINAS INC | 11 | Q2 2024 | 13.0% |
CULLINAN ONCOLOGY INC | 11 | Q2 2024 | 5.3% |
SILVERBACK THERAPEUTICS INC | 11 | Q2 2024 | 6.5% |
RELAY THERAPEUTICS INC | 10 | Q2 2024 | 5.1% |
EQRX INC | 8 | Q3 2023 | 23.5% |
KINNATE BIOPHARMA INC | 8 | Q3 2023 | 14.0% |
PMV PHARMACEUTICALS INC | 8 | Q3 2023 | 8.4% |
KRONOS BIO INC | 8 | Q3 2023 | 5.2% |
View Nextech Invest Ltd.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-09-03 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-01 |
View Nextech Invest Ltd.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.